Cosmos Holdings Inc. (NASDAQ:COSM – Get Rating) was the recipient of a significant increase in short interest during the month of November. As of November 30th, there was short interest totaling 7,220,000 shares, an increase of 10.7% from the November 15th total of 6,520,000 shares. Based on an average daily volume of 50,580,000 shares, the days-to-cover ratio is currently 0.1 days.
Cosmos Price Performance
COSM stock traded down $1.53 during trading on Friday, hitting $6.72. 1,584,527 shares of the company traded hands, compared to its average volume of 15,469,510. The stock’s 50-day simple moving average is $0.23 and its 200 day simple moving average is $0.36. The company has a quick ratio of 0.94, a current ratio of 1.05 and a debt-to-equity ratio of 0.86. Cosmos has a 1 year low of $0.07 and a 1 year high of $4.45.
Insider Transactions at Cosmos
In other news, CEO Grigorios Siokas acquired 801,261 shares of Cosmos stock in a transaction dated Monday, November 28th. The stock was purchased at an average cost of $0.62 per share, for a total transaction of $496,781.82. Following the completion of the purchase, the chief executive officer now directly owns 20,135,429 shares in the company, valued at approximately $12,483,965.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 39.70% of the company’s stock.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Cosmos stock. Virtu Financial LLC raised its holdings in Cosmos Holdings Inc. (NASDAQ:COSM – Get Rating) by 444.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 87,969 shares of the company’s stock after purchasing an additional 71,799 shares during the period. Virtu Financial LLC owned about 0.46% of Cosmos worth $33,000 at the end of the most recent quarter.
Cosmos Holdings Inc operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Cosmos, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Cosmos wasn’t on the list.
While Cosmos currently has a “N/A” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Comments are closed.